This pharmaceutical giant is building a new manufacturing site in Carlsbad
Pharmaceutical giant Novartis is building a new manufacturing facility in Carlsbad that will help expand the production of ...
C&EN2d
Novartis invests in 2 US radiopharmaceutical facilities
Novartis is making two investments in new radiopharmaceutical manufacturing sites in the US. The Swiss pharmaceutical giant will open a third US radioligand plant in Carlsbad, California, to serve the ...
Novartis4d
New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
A separate US-based single-arm OLIKOS Phase IIIb study showed that at 12 months, all clinically stable RMS patients who switched from intravenous (IV) anti-CD20 therapy to Kesimpta showed no new ...
Pharmaceutical Technology on MSN4d
FDA expands Novartis’ Kisqali label to include early breast cancer patients
Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...
Bloomberg L.P.6d
Novartis Breast Cancer Drug Helped Delay Return of Disease
Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that will be closely compared with a rival product from Eli Lilly. Novartis ...
Direct tumor radiation: can pharma’s $10 billion bet transform cancer treatment?
Pharmaceutical heavyweights like Bristol Myers Squibb, AstraZeneca, and Eli Lilly are betting big on radiopharmaceuticals, ...
FiercePharma9d
ESMO: Novartis, Daiichi, Gilead, Astellas and AZ excel in analysis of clinical value from new cancer meds
Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals ...
Novartis: Kisqali Reduces Recurrence Risk By 28.5% In Late-stage Early Breast Cancer Trial
Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Monday updated analysis from the pivotal Phase III ...
BioSpace10d
Sanofi Dips Into Red-Hot Radiopharma Space With $110M Licensing Deal
Sanofi will join Big Pharma peers Novartis, BMS and Eli Lilly in radioligands, striking a $110 million licensing deal with ...
Investing10d
Novartis stock faces tail risks from Kisqali patent litigation - BofA
BMO Capital maintained its Market Perform rating on Novartis, following discussions with the company's CFO Harry Kirsch. The meetings centered on the pharmaceutical giant's business outlook and ...